1 February 2026 - The February 2026 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The February issue of the Schedule includes has a few new/revised listings of note:

• Abiraterone acetate and prednisolone (Andriga-10) - new combination product
• Aflibercept (Afqlir) - new biosimilar medicine
• Calcipotriol monohydrate with betamethasone dipropionate (Wynzora) - new formulation
• Vanzacaftor with tezacaftor and deutivacaftor (Alyftrek) - new combination product

Read summary of PBS changes